Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
10
×
Tags
biotech
10
×
boston blog main
10
×
boston top stories
fda
life sciences
national blog main
national top stories
new york blog main
new york top stories
10
×
clinical trials
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
amgen
cancer
drugs
eli lilly
novartis
deals
startups
teva pharmaceutical
abbvie
allergan
alnylam pharmaceuticals
What
fda
10
×
drug
bio
new
roundup
won
approval
drugs
medicines
approved
class
companies
decades
developed
friday
medicine
migraine
news
oral
patients
time
acquire
activity
agency
ago
agreed
ahead
aimmune
allergy
alnylam
amgen
approvals
approve
arguments
asco
august
awaits
awarded
big
billion
Language
unset
Current search:
photo
×
fda
×
" boston blog main "
×
" new york top stories "
×
biotech
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines